NCT01327612 2021-02-21Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)AmgenPhase 2 Completed12 enrolled 21 charts
NCT00626704 2015-05-25Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue SarcomaAmgenPhase 1/2 Completed134 enrolled